Medexus Pharmaceuticals (TSE:MDP) Price Target Raised to C$6.00 at Stifel Nicolaus

Medexus Pharmaceuticals (TSE:MDP) had its target price boosted by Stifel Nicolaus from C$4.50 to C$6.00 in a research note published on Thursday morning,BayStreet.CA reports.

MDP has been the topic of a number of other reports. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Raymond James upgraded shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price target for the company in a research note on Wednesday, January 8th. Ventum Cap Mkts raised Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 17th. Finally, Leede Financial upgraded Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, January 22nd. Two research analysts have rated the stock with a buy rating and five have given a strong buy rating to the company’s stock. According to data from MarketBeat, Medexus Pharmaceuticals has a consensus rating of “Strong Buy” and an average price target of C$6.13.

Medexus Pharmaceuticals Trading Down 0.2 %

Medexus Pharmaceuticals stock opened at C$3.99 on Thursday. Medexus Pharmaceuticals has a 1-year low of C$1.47 and a 1-year high of C$5.56. The firm has a market cap of C$97.87 million, a P/E ratio of 79.80 and a beta of 1.96. The firm has a 50-day moving average of C$3.41 and a 200-day moving average of C$2.77.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.